Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies

  • Decibel Therapeutics Inc (NASDAQ: DBTXpresented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene.
  • Decibel presented the data at the Annual MidWinter Meeting of the Association for Research in Otolaryngology.
  • DB-OTO is delivered via surgical procedure during a standard cochlear implantation procedure.
  • Studies highlighted successful distribution and expression across the cochlear length, as well as well tolerated.
  • Data suggested hair cell-selective expression of otoferlin may enable greater efficacy and durability and minimize potential toxicity.
  • The therapy also demonstrated that DB-OTO restored normal hearing sensitivity in animal models of otoferlin deficiency.
  • Decibel is developing DB-OTO in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and expects to submit an Investigational New Drug/Clinical Trial Application for human trials in 2022.
  • Price Action: DBTX increased 4.94% at $18.90, and REGN is down 1.072% at $463.03 in market trading hours on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralHearing lossPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!